Arrowhead pharmaceuticals, inc. (ARWR)
Balance Sheet / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Sep'10
ASSETS
CURRENT ASSETS
Cash and cash equivalents

256,700

461,000

221,804

188,331

161,639

189,772

30,133

27,995

69,805

11,531

24,838

38,383

61,718

102,105

85,366

43,616

50,300

62,165

81,214

87,252

96,447

103,991

132,510

138,349

142,847

59,713

19,114

29,025

3,313

2,931

3,377

2,282

3,595

6,773

7,507

4,316

6,847

Restricted cash

-

-

-

1,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts receivable

1,265

1,345

661

2,044

13,422

3,168

327

14

16

149

67

937

580

60

75

-

-

-

-

-

-

127

-

-

-

75

75

-

-

115

9

-

22

-

-

-

58

Prepaid expenses

3,062

2,733

3,317

3,103

1,757

1,550

1,267

1,095

744

651

867

931

731

569

1,289

3,446

3,772

3,783

3,293

3,499

3,811

4,451

588

700

643

-

532

-

-

-

-

-

-

-

-

-

-

Other current assets

2,536

1,534

2,563

1,492

1,590

478

640

279

357

1,604

1,359

896

1,747

3,495

3,771

1,507

909

1,903

823

654

327

62

48

538

633

-

91

-

-

-

-

-

-

-

-

-

-

Short term investments

51,000

41,000

36,899

48,567

56,560

53,980

46,400

32,484

21,736

39,169

40,769

36,754

24,910

-

-

1,030

11,160

14,431

17,539

23,280

19,561

23,532

21,653

23,834

17,798

15,912

9,030

4,058

-

56

106

108

78

71

634

1,177

-

Other receivables

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

20

-

267

-

9

9

677

2,306

2,027

1,608

1,349

871

Prepaid expenses and other current assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

689

-

1,059

426

460

618

432

456

301

110

204

353

Note receivable, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,491

2,446

2,401

2,357

-

-

-

-

TOTAL CURRENT ASSETS

314,474

507,614

265,246

244,538

234,970

248,950

78,768

61,870

92,660

53,106

67,902

77,902

89,689

106,230

90,502

49,601

66,143

82,283

102,871

114,687

120,146

132,164

154,800

163,422

161,923

76,411

28,843

34,410

3,739

6,063

6,567

5,903

8,817

9,173

9,861

7,048

8,131

PROPERTY AND EQUIPMENT
Computers, office equipment and furniture

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

323

-

323

323

323

323

508

502

502

285

285

335

Research equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,319

-

3,346

3,186

3,225

3,319

3,409

4,459

4,450

3

3

752

Software

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

69

-

69

69

69

69

105

105

105

77

77

150

Leasehold improvements

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,749

-

2,749

2,749

2,749

2,749

2,762

2,749

2,591

-

-

78

Property, Plant and Equipment, Gross, Total

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6,461

-

6,489

6,329

6,367

6,461

6,786

7,817

7,650

365

365

1,317

Less: Accumulated depreciation and amortization

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,275

-

2,695

2,315

1,941

1,565

1,421

1,072

723

340

335

1,176

Property and equipment, net

29,362

26,434

23,214

17,074

13,378

13,920

13,935

14,029

14,582

14,932

15,513

16,134

15,714

16,165

15,386

12,274

4,381

4,666

4,526

4,108

4,127

4,124

3,872

3,674

3,290

3,186

3,513

3,793

4,013

4,426

4,895

5,365

6,745

6,927

25

29

141

Intangible assets, net

16,213

16,638

17,063

17,488

17,913

18,338

18,764

19,189

19,614

20,039

20,464

20,889

21,314

21,739

22,164

23,534

23,960

24,385

24,824

25,262

25,701

999

1,013

3,199

3,213

3,226

3,240

3,254

4,636

4,710

4,784

4,685

2,675

2,749

1,731

-

-

Long term investments

190,600

26,300

44,175

57,555

67,536

59,595

-

17,672

-

-

-

-

-

-

-

-

-

-

-

1,085

12,361

-

23,088

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Right-of-use assets

10,300

10,400

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Derivative asset and other non-current assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

30

30

30

280

312

170

160

161

284

-

Patents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,791

2,046

Note receivable, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

2,314

2,272

2,231

-

Investment in Nanotope Inc., equity basis

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

1,478

1,543

1,649

1,716

1,812

Investment in Leonardo Biosystems Inc., at cost

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

187

187

187

187

187

187

Other assets

144

144

144

170

141

141

141

141

141

141

141

154

152

122

122

122

122

45

45

45

41

7,041

41

41

166

13,094

30

3,284

4,666

4,740

5,064

5,219

4,518

6,961

6,001

6,211

4,081

Investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

17,806

-

26,284

34,048

9,867

1,702

-

-

-

-

-

-

-

-

-

-

Rent deposit

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

34

6

6

-

-

34

TOTAL ASSETS

561,075

587,601

349,845

336,828

333,940

340,947

111,609

112,903

126,998

88,220

104,022

115,081

126,871

144,258

128,176

85,533

94,607

111,381

132,267

145,190

162,378

162,136

182,816

196,622

202,641

92,692

37,329

41,488

12,419

15,231

16,527

16,488

20,080

23,062

15,888

13,289

12,354

LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES
Accounts payable

13,417

12,201

7,649

4,630

4,062

3,936

2,806

2,165

1,810

5,707

4,076

3,233

2,597

3,698

12,232

5,945

7,542

5,288

5,031

4,862

4,936

5,994

2,579

2,158

2,511

589

1,199

1,061

871

809

877

994

801

714

576

501

681

Accrued expenses

4,419

3,988

6,504

5,173

5,718

3,907

5,043

2,163

4,127

3,478

4,564

1,993

2,184

4,762

4,587

6,263

3,834

3,920

5,376

1,726

2,041

1,148

1,399

1,068

913

684

638

706

823

842

730

1,022

2,383

2,386

864

472

494

Due to Novartis

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued payroll and benefits

1,616

2,993

4,955

1,427

967

1,629

3,937

1,147

918

1,936

3,399

1,034

765

2,150

3,969

1,129

1,395

1,419

3,824

884

1,272

2,175

3,268

611

732

678

905

811

1,222

1,067

1,127

1,051

1,159

637

195

227

191

Lease liabilities

688

461

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent

-

-

173

173

173

212

307

440

440

440

440

440

440

440

440

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

33,174

54,034

77,769

75,681

90,889

124,925

0

943

1,565

1,875

5,269

13,283

21,169

25,584

2,569

26

65

109

103

71

65

109

103

71

65

109

103

71

65

109

37

71

69

101

-

-

-

Derivative liabilities

-

-

-

-

-

-

-

-

-

20

695

83

146

118

1,602

1,068

955

1,325

1,301

1,724

1,619

1,790

4,173

4,018

4,936

5,097

4,096

2,335

2,535

1,490

647

869

1,643

1,010

944

958

2,408

Capital lease obligation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

216

219

218

217

216

215

213

213

213

212

221

221

219

218

216

214

213

211

209

-

-

-

Note payable

-

-

-

-

-

-

223

219

216

212

208

204

201

197

194

144

-

-

-

-

-

-

50

50

1,050

1,050

971

925

880

935

100

-

-

-

-

-

500

Other current liabilities

17

16

16

-

-

-

46

46

46

46

46

46

46

46

46

46

46

46

46

46

59

65

58

58

60

588

588

546

546

606

1,592

1,592

106

-

-

-

-

TOTAL CURRENT LIABILITIES

53,333

73,695

97,070

87,087

101,812

134,611

12,364

7,127

9,123

13,716

18,701

20,319

27,551

36,998

25,643

14,840

14,058

12,328

15,900

9,532

13,210

11,497

11,847

8,250

10,482

9,018

8,725

6,677

7,164

6,077

5,327

5,815

6,375

5,060

2,581

2,159

4,276

LONG-TERM LIABILITIES
Lease liabilities, net of current portion

14,178

14,377

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Capital lease obligation, net of current portion

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

378

430

485

540

595

650

705

758

812

865

1,006

1,061

1,117

1,172

1,227

1,282

1,336

1,390

1,444

-

-

-

Contingent consideration obligations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5,862

5,862

5,862

5,862

3,970

3,970

3,970

3,970

-

-

-

1,595

-

-

-

-

-

-

-

-

-

-

Deferred rent, net of current portion

-

-

3,703

1,812

1,754

1,664

1,702

1,657

1,744

1,834

1,929

2,016

2,102

2,188

2,274

2,243

-

-

142

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue, net of current portion

-

-

5,035

22,258

29,732

33,171

-

-

-

-

-

625

1,250

5,180

2,500

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Note payable, net of current portion

-

-

-

-

-

-

2,101

2,158

2,215

2,270

2,325

2,378

2,431

2,482

2,533

2,583

-

-

-

-

-

-

-

-

-

-

50

50

50

50

839

793

748

702

606

560

-

Other non-current liabilities

-

-

-

-

-

-

200

200

200

200

200

200

200

200

200

200

329

336

200

346

350

253

255

1,752

1,755

1,757

163

337

272

270

269

93

-

106

135

-

-

TOTAL LONG-TERM LIABILITIES

14,178

14,377

8,738

24,071

31,487

34,835

4,003

4,016

4,159

4,304

4,454

5,219

5,983

10,051

7,508

11,268

6,622

6,684

6,745

4,913

4,971

4,929

4,984

2,564

2,621

2,763

2,869

1,504

1,494

1,548

2,391

2,224

2,138

2,253

742

560

-

Commitments and contingencies (Note 7)

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

STOCKHOLDERS’ EQUITY
Preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 and 15,652 shares issued and outstanding as of September 30, 2017 and September 30, 2016

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

-

0

0

0

0

0

0

Common stock, $0.001 par value; 145,000,000 shares authorized; 101,748,107 and 95,506,271 shares issued and outstanding as of March 31, 2020 and September 30, 2019, respectively

194

193

187

187

187

184

180

180

179

167

167

167

167

166

162

152

152

151

151

151

151

147

147

145

144

131

124

123

109

110

108

106

105

105

86

71

71

Additional paid-in capital

936,353

922,050

664,086

657,136

652,411

647,142

582,902

578,642

574,963

516,577

514,037

512,032

510,318

508,303

493,844

436,071

431,061

428,838

426,873

423,182

420,696

393,464

391,164

388,558

381,966

259,369

193,514

187,282

151,573

149,976

145,917

139,943

136,487

136,318

127,476

121,649

119,716

Accumulated other comprehensive income (loss)

-629

-195

-391

-103

-71

-43

-21

-3

25

23

33

-18

-30

-185

7

-30

59

-90

-136

-65

-63

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Subscription receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,500

1,016

1,000

2,665

3,897

900

-

-

Accumulated deficit

-441,800

-421,964

-419,290

-430,995

-451,331

-475,228

-487,265

-476,504

-460,898

-446,014

-432,815

-422,083

-416,563

-410,521

-398,435

-376,213

-356,792

-335,976

-316,712

-291,968

-276,032

-247,346

-224,771

-202,340

-190,711

-176,769

-166,140

-152,448

-146,369

-139,611

-134,997

-129,683

-121,692

-116,357

-113,871

-111,095

-110,742

Total Arrowhead Pharmaceuticals, Inc. stockholders' equity

494,118

500,083

244,591

226,225

201,195

172,055

95,796

102,314

114,270

70,754

81,422

90,097

93,891

97,763

95,579

59,980

74,481

92,923

110,176

131,299

144,751

146,264

166,540

186,362

191,399

82,731

27,498

34,956

5,312

8,974

10,012

9,365

12,235

16,169

12,791

10,625

9,045

Noncontrolling interest

-555

-555

-555

-555

-555

-555

-555

-555

-555

-555

-555

-555

-555

-555

-555

-555

-555

-555

-555

-555

-555

-555

-555

-555

-1,861

-1,821

-1,763

-1,651

-1,552

-1,370

-1,203

-916

-669

-420

-226

-56

-967

TOTAL STOCKHOLDERS’ EQUITY

493,563

499,528

244,036

225,670

200,640

171,500

95,241

101,759

113,715

70,199

80,867

89,542

93,336

97,208

95,024

59,425

73,926

92,368

109,621

130,744

144,196

145,709

165,985

185,807

189,537

80,910

25,734

33,305

3,760

7,604

8,808

8,448

11,566

15,748

12,564

10,569

8,078

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

561,075

587,601

349,845

336,828

333,940

340,947

111,609

112,903

126,998

88,220

104,022

115,081

126,871

144,258

128,176

85,533

94,607

111,381

132,267

145,190

162,378

162,136

182,816

196,622

202,641

92,692

37,329

41,488

12,419

15,231

16,527

16,488

20,080

23,062

15,888

13,289

12,354